BR112012008345A2 - regime de dosagem para a administração de um anticorpo biespecífico de epcamxcd3 - Google Patents
regime de dosagem para a administração de um anticorpo biespecífico de epcamxcd3Info
- Publication number
- BR112012008345A2 BR112012008345A2 BR112012008345A BR112012008345A BR112012008345A2 BR 112012008345 A2 BR112012008345 A2 BR 112012008345A2 BR 112012008345 A BR112012008345 A BR 112012008345A BR 112012008345 A BR112012008345 A BR 112012008345A BR 112012008345 A2 BR112012008345 A2 BR 112012008345A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- epcamxcd3
- bispecific
- dose
- dosage regimen
- Prior art date
Links
- 201000009030 Carcinoma Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24365109P | 2009-09-18 | 2009-09-18 | |
| EP09170715 | 2009-09-18 | ||
| US34414710P | 2010-06-01 | 2010-06-01 | |
| EP10164596 | 2010-06-01 | ||
| PCT/EP2010/063795 WO2011033105A1 (en) | 2009-09-18 | 2010-09-20 | Dosage regimen for administering an epcamxcd3 bispecific antibody |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112012008345A2 true BR112012008345A2 (pt) | 2016-08-09 |
Family
ID=43127167
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012008345A BR112012008345A2 (pt) | 2009-09-18 | 2010-09-20 | regime de dosagem para a administração de um anticorpo biespecífico de epcamxcd3 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20120244161A1 (enExample) |
| EP (1) | EP2477653A1 (enExample) |
| JP (1) | JP2013505223A (enExample) |
| KR (1) | KR20120083359A (enExample) |
| CN (1) | CN102711825A (enExample) |
| AU (1) | AU2010297258A1 (enExample) |
| BR (1) | BR112012008345A2 (enExample) |
| CA (1) | CA2774732A1 (enExample) |
| IL (1) | IL218637A0 (enExample) |
| IN (1) | IN2012DN03172A (enExample) |
| MX (1) | MX2012003175A (enExample) |
| NZ (1) | NZ598601A (enExample) |
| RU (1) | RU2012115480A (enExample) |
| SG (2) | SG10201405434VA (enExample) |
| WO (1) | WO2011033105A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6400470B2 (ja) | 2011-05-16 | 2018-10-03 | ジェネロン（シャンハイ）コーポレイション リミテッド | 多重特異性Ｆａｂ融合タンパク質および使用法 |
| WO2013083809A1 (en) | 2011-12-09 | 2013-06-13 | Amgen Research (Munich) Gmbh | Prevention of adverse effects caused by epcamxcd3 bispecific antibodies |
| GB201302447D0 (en) | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
| RS64664B1 (sr) | 2013-02-15 | 2023-11-30 | Bioverativ Therapeutics Inc | Gen optimizovanog faktora viii |
| WO2014131694A1 (en) | 2013-02-26 | 2014-09-04 | Roche Glycart Ag | Bispecific t cell activating antigen binding molecules |
| ES3012974T3 (en) * | 2014-01-08 | 2025-04-10 | Univ Leland Stanford Junior | Targeted therapy for lung cancer |
| US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| IL319047A (en) * | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| AU2016358296B2 (en) * | 2015-11-19 | 2020-05-21 | Revitope Limited | Functional antibody fragment complementation for a two-components system for redirected killing of unwanted cells |
| PH12018501628B1 (en) | 2016-02-01 | 2023-11-10 | Bioverativ Therapeutics Inc | Optimized factor viii genes |
| US12128102B2 (en) | 2016-03-08 | 2024-10-29 | Takeda Pharmaceutical Company Limited | Constrained conditionally activated binding proteins |
| US10870701B2 (en) | 2016-03-15 | 2020-12-22 | Generon (Shanghai) Corporation Ltd. | Multispecific fab fusion proteins and use thereof |
| WO2017167350A1 (en) * | 2016-03-30 | 2017-10-05 | Horst Lindhofer | Multispecific antibodies for use in the treatment of a neoplasm of the urinary tract |
| EP3409322A1 (en) * | 2017-06-01 | 2018-12-05 | F. Hoffmann-La Roche AG | Treatment method |
| KR20240170847A (ko) | 2017-09-08 | 2024-12-04 | 다케다 야쿠힌 고교 가부시키가이샤 | 제약된 조건적으로 활성화된 결합 단백질 |
| EP3847196A4 (en) | 2018-09-07 | 2023-01-04 | ITabMed (HK) Limited | BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF |
| CN114390938B (zh) | 2019-03-05 | 2025-03-21 | 武田药品工业有限公司 | 受约束的条件性活化的结合蛋白 |
| CN115279896A (zh) | 2019-09-30 | 2022-11-01 | 比奥维拉迪维治疗股份有限公司 | 慢病毒载体配制品 |
| IL299333A (en) | 2020-06-24 | 2023-02-01 | Bioverativ Therapeutics Inc | Methods for the purification of viral vectors |
| US20250002605A1 (en) * | 2021-11-19 | 2025-01-02 | Wuhan Yzy Biopharma Co., Ltd. | Bispecific antibody and use thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU612370B2 (en) | 1987-05-21 | 1991-07-11 | Micromet Ag | Targeted multifunctional proteins |
| HRP20110187T1 (hr) | 2003-10-16 | 2011-04-30 | Micromet Ag | Multispecifične deimunizirane tvari koje vežu cd3 |
| DK1874821T3 (da) * | 2005-04-26 | 2013-07-08 | Trion Pharma Gmbh | Kombination af antistoffer med glykokortikoider til behandling af kræft |
-
2010
- 2010-09-20 EP EP10755167A patent/EP2477653A1/en not_active Withdrawn
- 2010-09-20 IN IN3172DEN2012 patent/IN2012DN03172A/en unknown
- 2010-09-20 CN CN2010800523771A patent/CN102711825A/zh active Pending
- 2010-09-20 WO PCT/EP2010/063795 patent/WO2011033105A1/en not_active Ceased
- 2010-09-20 US US13/496,836 patent/US20120244161A1/en not_active Abandoned
- 2010-09-20 CA CA2774732A patent/CA2774732A1/en not_active Abandoned
- 2010-09-20 SG SG10201405434VA patent/SG10201405434VA/en unknown
- 2010-09-20 RU RU2012115480/15A patent/RU2012115480A/ru not_active Application Discontinuation
- 2010-09-20 JP JP2012529298A patent/JP2013505223A/ja active Pending
- 2010-09-20 AU AU2010297258A patent/AU2010297258A1/en not_active Abandoned
- 2010-09-20 KR KR1020127007677A patent/KR20120083359A/ko not_active Withdrawn
- 2010-09-20 SG SG2012016044A patent/SG179027A1/en unknown
- 2010-09-20 MX MX2012003175A patent/MX2012003175A/es not_active Application Discontinuation
- 2010-09-20 BR BR112012008345A patent/BR112012008345A2/pt not_active IP Right Cessation
- 2010-09-20 NZ NZ598601A patent/NZ598601A/en not_active IP Right Cessation
-
2012
- 2012-03-14 IL IL218637A patent/IL218637A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IN2012DN03172A (enExample) | 2015-09-25 |
| CN102711825A (zh) | 2012-10-03 |
| SG10201405434VA (en) | 2014-10-30 |
| MX2012003175A (es) | 2012-04-11 |
| US20120244161A1 (en) | 2012-09-27 |
| RU2012115480A (ru) | 2013-10-27 |
| JP2013505223A (ja) | 2013-02-14 |
| WO2011033105A1 (en) | 2011-03-24 |
| KR20120083359A (ko) | 2012-07-25 |
| CA2774732A1 (en) | 2011-03-24 |
| IL218637A0 (en) | 2012-05-31 |
| NZ598601A (en) | 2014-05-30 |
| AU2010297258A1 (en) | 2012-03-29 |
| EP2477653A1 (en) | 2012-07-25 |
| SG179027A1 (en) | 2012-04-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012008345A2 (pt) | regime de dosagem para a administração de um anticorpo biespecífico de epcamxcd3 | |
| CY1123688T1 (el) | Μεθοδοι για τη θεραπευτικη αντιμετωπιση ογκων χρησιμοποιωντας αμφιειδικο αντισωμα cd3xcd20 | |
| EA201290171A1 (ru) | Вводимые перорально кортикостероидные композиции | |
| NI201100194A (es) | Derivados de tieno [2, 3 - b] piridina como inhibidores de la replicación viral | |
| EP3501546A3 (de) | Cystein-wirkstoff konjugate und ihre verwendung | |
| BR112017024777A2 (pt) | uso de uma composiçao farmacêutica e de um antibiótico não absorvível para tratamento de transtorno do espectro autista referência cruzada a pedidos relacionados? | |
| BR112014031394A2 (pt) | composições e métodos para absorção transmucosa | |
| MX2010005631A (es) | Nuevos compuestos de hidrocarburo ciclicos para el tratamiento de enfermedades. | |
| ECSP19025350A (es) | Anticuerpos monoclonales optimizados contra el inhibidor de la vía del factor tisular (tfpi) | |
| CY1116874T1 (el) | Δοσολογικο σχημα για τη χορηγηση ενος cd19xcd3 αμφιειδικου αντισωματος | |
| WO2012142511A3 (en) | Orthomolecular compositions and their use in stabilizing the extracellular matrix | |
| CO6351803A2 (es) | Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi) | |
| BR112015001782A2 (pt) | método para produzir uma composição para o tratamento de um dente lesionado | |
| BR112015000136A2 (pt) | fibra alimentar para uso no tratamento de um efeito colateral gastrintestinal de uma nutrição ou medicamento | |
| BR112014030404A2 (pt) | proteína de fusão hgh-xten e seu uso no tratamento da deficiência de hormônio do crescimento | |
| BR112012000862A8 (pt) | composição farmacêutica oral, composição farmacêutica oral de baixa dose para administração crônica, método de tratamento ou retardo do inicio ou desenvolvimento de uma condição, método de tratamento da dor em um indivíduo que necessita deste medicamento, método de tratamento de uma condição em um indivíduo que necessita deste medicamento | |
| AR078224A1 (es) | Composicon para el tratamiento del cancer de prostata | |
| WO2012063134A3 (en) | Cardiac glycoside analogs in combination with emodin for cancer therapy | |
| BR112023004020A2 (pt) | Métodos para tratamento de asma em indivíduos pediátricos através da administração de um antagonista de il-4r | |
| BR112021025394A2 (pt) | Derivados de antraciclina, conjugados de fármaco e molécula de ligação ao alvo, uso de conjugado de fármaco e molécula de ligação ao alvo, método de tratamento de uma doença em um paciente em necessidade de tratamento, e composição farmacêutica | |
| BR112015001627A2 (pt) | composição farmacêutica, respectivos usos e método para diminuir a frequência de micção | |
| NZ588886A (en) | Use of dronedarone alone or in combination for preparing a medicament for the treatment of patients with arrhythmia and having an increase of creatinine level | |
| ATE485037T1 (de) | Krebsbehandlung mittels fts und 2-deoxyglucose | |
| AR076479A1 (es) | Composiciones farmaceuticas para terapias de mantenimiento que contienen como ingrediente activo un anticuerpo que reconoce el antigeno leucocitario humano (hla) de clase i | |
| BR112013027006A2 (pt) | método de produzir substâncias com gás supersaturado, dispositivo de distribuição transdérmica do mesmo |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 6A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |
|
| B25E | Requested change of name of applicant rejected |
Owner name: MICROMET AG (DE) |